«This is one
of the very first studies
of human iPSC models for type 2 diabetes, and it points out the
power of this technology to look at the nature
of diabetes, which is complex and may be different in different individuals,» says C. Ronald Kahn, MD, Joslin's Chief
Academic Officer and the Mary K. Iacocca Professor
of Medicine at Harvard Medical School.